|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Israel BB, Tilghman SL, Parker-Lemieux K
and Payton-Stewart F: Phytochemicals: Current strategies for
treating breast cancer. Oncol Lett. 15:7471–7478. 2018.PubMed/NCBI
|
|
3
|
Calaf GM and Roy D: Metastatic genes
targeted by an antioxidant in an established radiation- and
estrogen-breast cancer model. Int J Oncol. 51:1590–1600. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cristofanilli M and Fortina P: Circulating
tumor DNA to monitor metastatic breast cancer. N Engl J Med.
369:932013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Si W, Shen J, Du C, Chen D, Gu X, Li C,
Yao M, Pan J, Cheng J, Jiang D, et al: A miR-20a/MAPK1/c-Myc
regulatory feedback loop regulates breast carcinogenesis and
chemoresistance. Cell Death Differ. 25:406–420. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen S, Wang Y, Zhang JH, Xia QJ, Sun Q,
Li ZK, Zhang JG, Tang MS and Dong MS: Long non-coding RNA PTENP1
inhibits proliferation and migration of breast cancer cells via AKT
and MAPK signaling pathways. Oncol Lett. 14:4659–4662. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fabbri M: TLRs as miRNA receptors. Cancer
Res. 72:6333–6337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Torres S, García-Palmero I, Bartolomé RA,
Fernandez-Aceñero MJ, Molina E, Calviño E, Segura MF and Casal JI:
Combined miRNA profiling and proteomics demonstrates that different
miRNAs target a common set of proteins to promote colorectal cancer
metastasis. J Pathol. 242:39–51. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X, Bi L, Wang Q, Wen M, Li C, Ren Y,
Jiao Q, Mao JH, Wang C, Wei G and Wang Y: miR-1204 targets VDR to
promotes epithelial-mesenchymal transition and metastasis in breast
cancer. Oncogene. 37:3426–3439. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
El Helou R, Pinna G, Cabaud O, Wicinski J,
Bhajun R, Guyon L, Rioualen C, Finetti P, Gros A, Mari B, et al:
miR-600 acts as a bimodal switch that regulates breast cancer stem
cell fate through WNT signaling. Cell Rep. 18:2256–2268. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu W, Xu Y, Guan H and Meng H: Clinical
potential of miR-940 as a diagnostic and prognostic biomarker in
breast cancer patients. Cancer Biomark. 22:487–493. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao YL, Dong W, Li YZ and Han W:
MicroRNA-653 inhibits thymocyte proliferation and induces thymocyte
apoptosis in mice with autoimmune myasthenia gravis by
downregulating TRIM9. Neuroimmunomodulation. 26:7–18. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan L, Feng Y, Li L, et al: Effect of
microRNA-653 on biological characteristics of human non-small cell
lung cancer cells by targeting OIP5 gene and regulating mTOR
signaling pathway. J Mod Oncol. 26:831–837. 2018.
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tokunaga E, Oki E, Egashira A, Sadanaga N,
Morita M, Kakeji Y and Maehara Y: Deregulation of the Akt pathway
in human cancer. Curr Cancer Drug Targets. 8:27–36. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Paladini L, Fabris L, Bottai G, Raschioni
C, Calin GA and Santarpia L: Targeting microRNAs as key modulators
of tumor immune response. J Exp Clin Cancer Res. 35:1032016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rupaimoole R, Calin GA, Lopez-Berestein G
and Sood AK: miRNA deregulation in cancer cells and the tumor
microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morgensztern D and McLeod HL:
PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer
Drugs. 16:797–803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mayer IA and Arteaga CL: The PI3K/AKT
pathway as a target for cancer treatment. Annu Rev Med. 67:11–28.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brand F, Schumacher S, Kant S, Menon MB,
Simon R, Turgeon B, Britsch S, Meloche S, Gaestel M and Kotlyarov
A: The extracellular signal-regulated kinase 3 [mitogen-activated
protein kinase 6 (MAPK6)]-MAPK-activated protein kinase 5 signaling
complex regulates septin function and dendrite morphology. Mol Cell
Biol. 32:2467–2478. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Al-Mahdi R, Babteen N, Thillai K, Holt M,
Johansen B, Wetting HL, Seternes OM and Wells CM: A novel role for
atypical MAPK kinase ERK3 in regulating breast cancer cell
morphology and migration. Cell Adh Migr. 9:483–494. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Evtimova V, Schwirzke M, Tarbé N,
Burtscher H, Jarsch M, Kaul S and Weidle UH: Identification of
breast cancer metastasis-associated genes by chip technology.
Anticancer Res. 21:3799–3806. 2001.PubMed/NCBI
|
|
25
|
Liang B, Wang S, Zhu XG, Yu YX, Cui ZR and
Yu YZ: Increased expression of mitogen-activated protein kinase and
its upstream regulating signal in human gastric cancer. World J
Gastroenterol. 11:623–628. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Long W, Foulds CE, Qin J, Liu J, Ding C,
Lonard DM, Solis LM, Wistuba II, Qin J, Tsai SY, et al: ERK3
signals through SRC-3 coactivator to promote human lung cancer cell
invasion. J Clin Invest. 122:1869–1880. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou YH, Huang YY and Ma M: MicroRNA-138
inhibits proliferation and induces apoptosis of laryngeal carcinoma
via targeting MAPK6. Eur Rev Med Pharmacol Sci. 22:5569–5575.
2018.PubMed/NCBI
|
|
28
|
Wu J, Zhao Y, Li F and Qiao B: MiR-144-3p:
A novel tumor suppressor targeting MAPK6 in cervical cancer. J
Physiol Biochem. 75:143–152. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lv P, Qiu X, Gu Y, Yang X, Xu X and Yang
Y: Long non-coding RNA SNHG6 enhances cell proliferation, migration
and invasion by regulating miR-26a-5p/MAPK6 in breast cancer.
Biomed Pharmacother. 110:294–301. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Potapova O, Gorospe M, Dougherty RH, Dean
NM, Gaarde WA and Holbrook NJ: Inhibition of c-Jun N-terminal
kinase 2 expression suppresses growth and induces apoptosis of
human tumor cells in a p53-dependent manner. Mol Cell Biol.
20:1713–1722. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu C, Huang S, Wu F and Ding H: miR-98
inhibits cell proliferation and induces cell apoptosis by targeting
MAPK6 in HUVECs. Exp Ther Med. 15:2755–2760. 2018.PubMed/NCBI
|
|
32
|
Hao W, Zhao ZH, Meng QT, Tie ME, Lei SQ
and Xia ZY: Propofol protects against hepatic ischemia/reperfusion
injury via miR-133a-5p regulating the expression of MAPK6. Cell
Biol Int. 41:495–504. 2017. View Article : Google Scholar : PubMed/NCBI
|
